This is a placebo-controlled, double-blind study to evaluate the safety and efficacy of two doses of DR-3001 in women with overactive bladder who have symptoms of predominant or pure urge incontinence, urinary urgency and elevated urinary frequency

This is a multi-center, randomized, placebo-controlled study to compare two doses of DR-3001 to placebo for a 12-week treatment period. The overall duration of patient participation will be for approximately 19 weeks. Patients will be required to keep a daily diary record of study medication use and incontinence episodes

Inclusion Criteria:

• Diagnosis of overactive bladder and incontinence for at least 6 months
• Using birth control or menopausal
• Willing to discontinue current medication for overactive bladder

Exclusion Criteria:

• Pregnant or given birth in the last 6 months
• Three or more urinary tract infections a year
• Uncontrolled glaucoma, hypertension, diabetes or myasthenia gravis
• History of bladder cancer, ulcerative colitis or severe constipation
• Any contraindication to vaginal delivery systems